Advertisement
Screener

Cue Biopharma, Inc. (CUE) Increase (Decrease) in Other Operating Assets

2.8 / 5 stars · 68/120 Roast Me

Cue Biopharma, Inc. Increase (Decrease) in Other Operating Assets

Cue Biopharma, Inc. (CUE) reported Increase (Decrease) in Other Operating Assets of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-21.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2023-03-21

  • Cue Biopharma, Inc. increase (decrease) in other operating assets for the quarter ending 2022-12-31 was $0.00.
  • Cue Biopharma, Inc. increase (decrease) in other operating assets for the quarter ending 2022-09-30 was $0.00.
  • Cue Biopharma, Inc. increase (decrease) in other operating assets for the quarter ending 2021-12-31 was $0.00.
  • Cue Biopharma, Inc. increase (decrease) in other operating assets for the quarter ending 2021-09-30 was $0.00.
  • Cue Biopharma, Inc. increase (decrease) in other operating assets for fiscal 2022 was $0.00.
  • Cue Biopharma, Inc. increase (decrease) in other operating assets for fiscal 2021 was -$250.00K, a 5129.17% decline from fiscal 2020.
  • Cue Biopharma, Inc. increase (decrease) in other operating assets for fiscal 2020 was $4.97K.
  • Cue Biopharma, Inc. increase (decrease) in other operating assets for fiscal 2019 was -$123.44K.
Period endIncrease (Decrease) in Other Operating Assets 3 monthIncrease (Decrease) in Other Operating Assets 6 monthIncrease (Decrease) in Other Operating Assets 9 monthIncrease (Decrease) in Other Operating Assets 12 month
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21
$0.00
derived: sum of 2 quarters · filed 2023-03-21
$0.00
10-K · filed 2023-03-21
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$0.00
10-Q · filed 2022-11-14
2022-06-30$0.00
10-Q · filed 2022-08-04
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21
$0.00
derived: sum of 2 quarters · filed 2023-03-21
$0.00
derived: sum of 3 quarters · filed 2023-03-21
-$250.00K
10-K · filed 2023-03-21
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$0.00
derived: sum of 2 quarters · filed 2022-11-14
-$250.00K
10-Q · filed 2022-11-14
-$495.03K
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$250.00K
10-Q · filed 2022-08-04
-$495.03K
derived: sum of 3 quarters · filed 2022-08-04
2021-03-31-$250.00K
10-Q · filed 2022-05-10
-$495.03K
derived: sum of 2 quarters · filed 2022-05-10
2020-12-31-$245.03K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16
$4.97K
10-K · filed 2022-03-16
2020-09-30$250.00K
10-Q · filed 2021-11-09
2019-12-31-$115.44K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09
-$123.44K
10-K · filed 2021-03-09
2019-09-30-$8.00K
10-Q · filed 2019-11-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
MACROGENICS INC (MGNX)United States$0.242B-20.11
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55